Clinical Trial Update: A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion [Phase 2]

View source ↗

Summary

Phase 2 trial update on ABT-199 (venetoclax) in relapsed/refractory or previously untreated chronic lymphocytic leukemia with 17p deletion; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ABT-199 (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia, 17p Deletion | Phase 2 | Status: COMPLETED | Results posted: 2021-12-16